SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on CRISPR Therapeutics CTX310 clinical data and other pipeline readouts, with traders debating whether encouraging results can shift sentiment toward its in-vivo gene-editing and autoimmune programs. Optimism about the catalysts and Casgevys commercial ramp is tempered by frustration that the stock has remained range-bound and may not respond to positive developments.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply through 2027 has fueled concern about pricing and CorMedixs largest revenue driver. Traders are divided: some see a lasting revenue risk, while others argue DaVitas estimate is preliminary and not a definitive forecast of CMS rates or CorMedix revenue.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results sparked debate after stronger-than-expected earnings and comparable sales were offset by a revenue miss, with the China restructuring weighing on reported sales and the stocks reaction remaining subdued. Bulls point to improving U.S. traffic and the turnaround outlook, while bears question the valuation and whether growth can justify it.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported Lundbeck interest in acquiring Xeris has fueled takeover speculation, with traders debating whether other buyers could emerge; the company has said it is not for sale, and no deal is confirmed. Others are focused on the upcoming quarterly results and Recorlev growth, as well as the longer-term XP-8121 Phase 3 opportunity.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported multibillion-dollar Binance security breach is driving attention, with traders focused on suspended withdrawals and concerns about exchange security and customer funds. The community debates whether Binance can cover the losses and whether BNBs limited decline understates the risk; claims of an inside job or specific perpetrators remain speculation.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is drawing attention for choppy trading around technical resistance, with traders split on whether a breakout can hold or shares will retreat toward support. Bullish options activity and optimism about parks, streaming and recent earnings compete with frustration over the stocks long-term performance.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos decline is being tied to an analyst price-target cut amid concerns that networking growth may be peaking and the stocks valuation could compress; the firm kept its rating unchanged. Traders are split between calling the selloff an overreaction given AI-networking demand and seeing continued technical weakness.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of market breadth and the rotation between mega-cap tech and the broader S&P 500: traders have highlighted periods of equal-weight outperformance as participation widens beyond AI and tech leaders. The reaction is mixed, with some viewing the rotation as healthy broadening and others warning that recent RSP weakness signals deteriorating breadth and renewed concentration in a few large stocks.

Pudgy Penguins (PENGU) is a cryptocurrency launched in 2024and operates on the Solana platform. Pudgy Penguins has a current supply of 76,724,221,264.3 with 62,860,396,090.04 in circulation. The last known price of Pudgy Penguins is 0.00754361 USD and is up 6.59 over the last 24 hours. It is currently trading on 540 active market(s) with $130,377,930.32 traded over the last 24 hours. More information can be found at https://www.pengu.pudgypenguins.com.

Pudgy Penguins

PENGU is drawing attention around its pullback and attempts to hold a technical support zone, with traders debating whether it can rebound or break lower. Dip buyers point to possible support and broader crypto-market recovery, while bears cite persistent selling, weak momentum and a lack of fresh catalysts.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as its shares and the wider mining sector face pressure, with repeated technical analysis suggesting the correction may not be over. Traders are divided between expecting further weakness and treating the pullback as an opportunity to add, while gold-price and interest-rate concerns weigh on near-term sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +1.89% and +0.96%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates

Integra (IART) delivered earnings and revenue surprises of +5.36% and -0.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Neuronetics Q2 Earnings Call Highlights

Neuronetics Q2 Earnings Call Highlights...

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of +54.55% and +3.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Shoulder Innovations, Inc. (SI) Reports Q2 Loss, Beats Revenue Estimates

Shoulder Innovations, Inc. (SI) delivered earnings and revenue surprises of 0.00% and +1.93%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Is Neuronetics Stock Soaring Monday?

BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.read more...

Neuronetics Q1 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported first-quarter 2026 results that management said were largely in line with expectations, as the company balanced growth in its Greenbrook clinic business with a...

Neuronetics (NASDAQ:STIM) Announces Earnings Results, Beats Estimates By $0.01 EPS

Neuronetics (NASDAQ:STIM - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates...

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of +5.88% and +0.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 2003 and is headquartered in Malvern, PA.

Neuronetics Inc

Why Is STIM Stock Rallying 16% After-Hours? 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The shareholder instead recommended that the company’s &nbsp;clinic business operate on a standalone basis.</li><li>Neuronetics on Monday reaffirmed its fiscal year 2026 guidance of revenue in the range of $160 million-$166 million and gross margin of 47% to 49%.&nbsp;</li><li>The company also said that Steven E. Pfanstiel will depart from his role as CFO to pursue an opportunity outside the company.</li></ul>Shares of Neuronetics Inc. (STIM) jumped as much as 16% after-hours on Monday before paring back gains after the firm’s largest independent shareholder called upon its board of directors to conduct a review of strategic alternatives, highlighting the company’s finite resources.Jorey Chernett, who owns about 14% of the company's outstanding shares, urged the board to consider options including the sale of its Transcranial Magnetic Stimulation (TMS) business unit under which it operates treatment centers across the U.S.The shareholder instead recommended that the company’s clinic business operate on a standalone basis. According to Chernett, the company has two compelling high-quality assets with expanding total addressable markets. The company also noted that the expected synergies of combining TMS and Greenbrook in December 2024 have not materialized thus far.“Since the December 2024 acquisition, pure-play peers have dramatically outperformed STIM and now trade at substantially higher multiples,” they said, while adding that the company has only finite resources which cannot serve both distinct businesses.<h2 class="st-heading-2">CFO Exit</h2>Neuronetics on Monday reaffirmed its fiscal year 2026 guidance of revenue in the range of $160 million to $166 million and gross margin of 47% to 49%.The company also said that Steven E. Pfanstiel will depart from his role as Chief Financial Officer (CFO) to pursue an opportunity outside the company. The company is now on the lookout for a replacement for Pfanstiel, who will remain with the company through May 1.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around STIM stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/STIM">STIM stock</a> has dropped 50% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/orgo-stock-rallies-after-hours-on-clearing-regulatory-pathway-for-pain-relief-treatment/cZJ4yLURIYY">ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

STIM Stock - Neuronetics’ largest independent shareholder called upon its board of directors to conduct a review of strategic alternatives on Monday. 

Neuronetics’ largest independent shareholder called upon its board of directors to conduct a review of strategic alternatives on Monday. 


iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$STIM I like when earnings are reported before the market opens…. Good news could send this small stock IMO.   Some solid investors involved….. pumped .. action very nice today!

Jack

$STIM MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release third quarter 2026 financial and operating results prior to market open on Wednesday, November 4, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

$STIM meeting some psychological resistance at $2, curious how long it will hover here before dipping lower

Tree_Llama

$STIM Fear SP will reach $1.25 support before rebounding. Market has been 💩 which isn’t good for high risk small cap stocks like STIM

Feed

News

Sentiment

Earnings

Fundamentals

Info

STIM Neuronetics Inc

Fundamentals

Latest STIM News